Evidence map›Paper›PMID 34885992›Full record

ReviewMolecules (Basel, Switzerland)2021

Anticancer Properties of Eugenol: A Review.

Ali T Zari, Talal A Zari, Khalid Rehman Hakeem

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 186 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Exploring the Therapeutic Potential ofAnti-cancer agents in medicinal chemistry · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  15. Article
  16. Review
  17. Comparative Evaluation ofPharmaceutics · 2025
    Article
  18. Article
  19. The combination of water extracts ofNutrition research and practice · 2025
    Article
  20. Evaluating the Chemical Composition and Antitumor Activity ofInternational journal of molecular sciences · 2025
    Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ali T ZariDepartment of Biological Sciences, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.
Talal A ZariDepartment of Biological Sciences, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.
Khalid Rehman HakeemDepartment of Biological Sciences, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-7824-4695
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional cancer treatments have shown several unfavourable adverse effects, as well as an increase in anticancer drug resistance, which worsens the impending cancer therapy. Thus, the emphasis is currently en route for natural products. There is currently great interest in the natural bioactive components from medicinal plants possessing anticancer characteristics. For example, clove (

Indexed as

AnimalsAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsApoptosisCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationClove OilEugenolHumansNeoplasmsOils, VolatilePhytochemicalsPhytotherapyAnti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsClove OilEugenolOils, VolatilePhytochemicalsanticancer propertiesanti-inflammatoryantioxidantapoptosisautophagyclove oileugenolinvasionmetastasismigrationproliferation

Identifiers

PMID34885992
PMCPMC8659182
OpenAlexW4200443794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.